154 related articles for article (PubMed ID: 35301949)
1. Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma.
Kumar AR; Devan AR; Nair B; Nair RR; Nath LR
Curr Cancer Drug Targets; 2022; 22(9):725-740. PubMed ID: 35301949
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
3. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Making the most of mucin: a novel target for tumor immunotherapy.
Barratt-Boyes SM
Cancer Immunol Immunother; 1996 Nov; 43(3):142-51. PubMed ID: 9001567
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
[TBL] [Abstract][Full Text] [Related]
7. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
8. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
9. Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.
Gückel B; Rentzsch C; Nastke MD; Marmé A; Gruber I; Stevanović S; Kayser S; Wallwiener D
J Cancer Res Clin Oncol; 2006 Apr; 132(4):265-74. PubMed ID: 16374613
[TBL] [Abstract][Full Text] [Related]
10. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
12. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
13. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.
Kim M; Lee SJ; Shin S; Park KS; Park SY; Lee CH
Sci Rep; 2018 Jul; 8(1):10668. PubMed ID: 30006566
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in hepatocellular carcinoma.
Buonaguro L; Mauriello A; Cavalluzzo B; Petrizzo A; Tagliamonte M
Ann Hepatol; 2019; 18(2):291-297. PubMed ID: 31047849
[TBL] [Abstract][Full Text] [Related]
15. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
16. HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.
Kikodze N; Mazmishvili K; Iobadze M; Rekhviashvili Kh; Nanava N; Pantsulaia I; Mizandari M; Janikashvili N; Chikovani T
Georgian Med News; 2015 Sep; (246):78-84. PubMed ID: 26355320
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
Yu M; Li Z
Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies for hepatocellular carcinoma.
Butterfield LH
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S232-41. PubMed ID: 15508089
[TBL] [Abstract][Full Text] [Related]
19. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Khanam A; Kottilil S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613878
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for hepatocellular carcinoma.
Zhou M; Liu B; Shen J
Clin Exp Med; 2023 Jul; 23(3):569-577. PubMed ID: 36001163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
